Evidence map›Paper›PMID 32782678›Full record

ArticleInternational journal of clinical and experimental pathology2020

Early diagnostic and prognostic value of serum exosomal miR-1246 in non-small cell lung cancer.

Dawei Huang, Di Qu

Abstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Exosomal microRNAs: impact on cancer detection, treatment, and monitoring.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dawei HuangDepartment of Medical Affairs, The Second Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang Province, China.
Di QuDepartment of Medical Oncology, The Second Affiliated Hospital of Harbin Medical University Harbin, Heilongjiang Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is one of the most common malignant tumors. A growing body of evidence has demonstrated that circulating microRNAs (miRNAs) have great potential for the diagnosis and prognosis of lung cancer. In this study, we aimed to determine the clinical significance of serum exosomal miR-1246 in non-small cell lung cancer (NSCLC). Real-time PCR was performed to measure the expression level of serum exosomal miR-1246 in NSCLC patients. The correlations between the serum exosomal miR-1246 level and prognosis of NSCLC were then investigated. The expression of serum exosomal miR-1246 was significantly increased in NSCLC patients. Receiver operating characteristic (ROC) analysis showed that serum exosomal miR-1246 showed good performance for discriminating NSCLC patients from healthy controls and patients with non-malignant respiratory diseases. The level of serum exosomal miR-1246 was decreased following treatments, but increased in the cases with recurrence. In addition, serum exosomal miR-1246 level was strongly associated with lymph node metastasis and TNM stage. Survival analysis showed that the patients in the high serum exosomal miR-1246 group had poorer overall survival and disease-free survival. Multivariate analysis showed that serum exosomal miR-1246 level was an independent prognostic factor for NSCLC. In conclusion, serum exosomal miR-1246 might be a useful diagnostic and prognostic biomarker for NSCLC.

Indexed as

biomarkerearly diagnosisnon-small cell lung cancerprognosisSerum exosomal miR-1246

Identifiers

PMID32782678
PMCPMC7414461

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.